How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose
NCT ID: NCT00574041
Last Updated: 2008-09-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
19 participants
INTERVENTIONAL
2007-06-30
2008-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis
NCT00599274
Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients
NCT00784836
Avonex 15 Year Long Term Follow-up Study
NCT00525343
Open-Label Safety Extension Study of Avonex
NCT00915460
Evaluation of Brain Atrophy in CIS Patients on Avonex
NCT01592474
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
titrated dose of Avonex
Interferon beta-1a
injected, once a week
2
full dose Avonex
Interferon beta-1a
injected, once a week
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Interferon beta-1a
injected, once a week
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Use of AVONEX, but not other interferon therapies, in the 3 months prior to randomisation into the study
* A clinically significant infectious illness (e.g., cellulitis, abscess, pneumonia, septicemia) within 30 days prior to randomisation.
* History of seizure in the 3 months prior to randomisation
* History of suicidal ideation or severe depression within the 3 months prior to randomisation.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biogen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Biogen Idec
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Biogen-Idec Investigator
Role: PRINCIPAL_INVESTIGATOR
Biogen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Coordinating Research Site
Malvern, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AUS-8002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.